China’s in-vitro diagnostics (IVD) services provider Virtue has raised 200 million yuan ($30 million) in a Series A round funding led by Shanghai-based life science-focused investment firm Lilly Asia Ventures (LAV), per a company statement on December 15.
New York-listed American PerkinElmer’s investment arm PKI Ventures also participated in the round.
LAV and PKI are holding 18.76 per cent and 12.99 per cent stake respectively in the company.
Virtue, set up in 2019 in East China’s Suzhou, specialises in early-stage screening related to oncology, maternity and infant care, and chronic diseases.
Shanghai Fenglve Management is the largest shareholder in Virtue with a 36.19 per cent stake, followed by Shanghai Xieqian Management at 22.68 per cent.
CHINA DEAL MONITOR
DealStreetAsia has also put together a table listing out all prominent venture capital transactions in the Greater China region on December 17 – 18, 2020.
